LitAlert ~~ GeneLit.com

    • Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment.
    • Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I.
    • Expert Rev Pharmacoecon Outcomes Res. 2023 Jan 17. doi: 10.1080/14737167.2023.2169137. Epub ahead of print.

    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    • Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
    • Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.

    • Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review.
    • Briggs LG, Steele GL, Qian ZJ, Subbana S, Alkhatib KY, Labban M, Langbein BJ, Nguyen DD, Cellini J, Kilbridge K, Kibel AS, Trinh QD, Rana HQ, Cole AP.
    • JCO Oncol Pract. 2023 Jan 12:OP2200634. doi: 10.1200/OP.22.00634. Epub ahead of print.
    • Review

    • Implementation of a Telehealth Genetic Testing Station to Deliver Germline Testing for Men With Prostate Cancer.
    • Kwon DH, Gordon KM, Tong B, Borno HT, Beigh M, Fattah D, Schleicher A, Aggarwal RR, Blanco AM, Small EJ, Dhawan M.
    • JCO Oncol Pract. 2023 Jan 12:OP2200638. doi: 10.1200/OP.22.00638. Epub ahead of print.